Dr Reddy's inks $370 million licensing deal to sell Immutep's cancer drug Eftilagimod Alfa
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
The study met its primary endpoint and all 11 secondary efficacy endpoints
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
MRI is particularly valuable in pediatric care due to its non-invasive nature
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Subscribe To Our Newsletter & Stay Updated